The ASCI, a venerable medical honor society with a membership exceeding 3,500 physician-scientists across diverse clinical and research disciplines, serves to promote the integration of laboratory science and clinical medicine. This society’s early-career awards are crafted to acknowledge groundbreaking research accomplishments by investigators at critical stages in their careers and to foster their professional development and immersion within an influential scientific community.

Dr. Semra Etyemez, who holds research associate appointments in both obstetrics and gynecology as well as psychiatry, was awarded the ASCI Emerging-Generation Award. This accolade is bestowed upon promising post-MD researchers who have yet to secure faculty positions but who are deeply engaged in intensive, high-impact investigations. Her work probes the biological substrates underlying perinatal mood and anxiety disorders, an area of profound clinical significance due to the high prevalence and deleterious impact of these conditions on maternal and child health.

In her research, Dr. Etyemez aims to elucidate the complex neurobiological changes occurring during the perinatal period, with a particular focus on identifying reliable biomarkers that could predict or reflect the onset of mood disturbances. This precision approach aspires to pave the way for novel therapeutic strategies that prevent or mitigate perinatal mental illness, a field historically hindered by limited mechanistic understanding. Dr. Etyemez emphasizes how this award highlights the critical importance of advancing perinatal mental health research, which remains an underexplored yet vital domain affecting millions of women worldwide.

Parallel to Dr. Etyemez’s achievements, Dr. Jesse Platt, an assistant professor specializing in gastroenterology and hepatology, received the ASCI Young Physician-Scientist Award. This distinction is reserved for early faculty members who have demonstrated exceptional research accomplishments with strong potential to influence the trajectory of their fields. Dr. Platt’s laboratory investigates the dynamic intracellular organization and protein mobility, fundamental biological processes that govern cellular function and contribute to disease pathogenesis.

His research centers on decoding how cellular architecture modulates molecular interactions, with implications for metabolic diseases and other complex disorders. By dissecting the spatial-temporal behavior of proteins within the cellular milieu, Dr. Platt endeavors to uncover mechanistic insights that may ultimately be harnessed to formulate innovative therapeutic interventions. He notes that receiving this award affirms the impact of his work and invigorates his commitment to scientific exploration during this pivotal stage of his career.

Both scientists are slated to receive their awards at the upcoming ASCI annual meeting in April, an event that convenes leading physician-scientists from across medical disciplines to exchange ideas and foster collaboration. This forum offers an invaluable platform for early-career investigators like Dr. Etyemez and Dr. Platt to engage with esteemed colleagues, broaden their professional networks, and refine their leadership skills through targeted workshops and discussion panels.

Beyond the ceremony, the honorees will participate in ongoing ASCI activities throughout the year, including leadership development programs, mentorship from senior members, and scientific symposia that encourage interdisciplinary dialogue. These opportunities are designed to enhance the careers of emerging physician-scientists by providing access to resources essential for successful navigation of the academic research landscape.

Dr. Etyemez’s research occupies a critical nexus between psychiatry and obstetrics, emphasizing the necessity of understanding the neuroendocrine and molecular mechanisms that modulate maternal mental health. The perinatal period, encompassing pregnancy and the postpartum phase, is marked by profound hormonal fluctuations that impact brain function. Her work strives to translate these biological insights into clinical applications that can improve screening, diagnosis, and treatment strategies for mood and anxiety disorders in this unique patient population.

In contrast, Dr. Platt’s investigations delve into the realm of cell biology with a focus on gastroenterological conditions that pose significant global health burdens. By elucidating how intracellular organization influences disease mechanisms, his findings may revolutionize the conceptual framework guiding the development of therapies for chronic metabolic and liver diseases, among others. His approach exemplifies how fundamental research at the molecular level can culminate in translational breakthroughs with real-world clinical relevance.

Together, these two awardees underscore the breadth and depth of contemporary physician-scientist research at Weill Cornell Medicine. Their work not only advances our biological understanding of complex diseases but also highlights the symbiotic relationship between clinical experience and scientific investigation that propels medical innovation. The acknowledgment by ASCI serves as both a recognition of their past accomplishments and an encouragement for continued pioneering efforts to improve patient outcomes.

As the scientific community anticipates the presentation of these awards, the broader impact of such honors becomes clear: They inspire a new cadre of physician-scientists to pursue investigative careers that bridge bench and bedside. By fostering an environment that supports early-career researchers, organizations like ASCI play a pivotal role in ensuring the sustainability of biomedical discovery and the future of clinical medicine.

In summary, Dr. Semra Etyemez and Dr. Jesse Platt’s recognition by the American Society for Clinical Investigation not only celebrates their individual scientific contributions but also epitomizes the mission of physician-scientist training programs that cultivate leaders dedicated to improving human health through research. Their awarded work in perinatal mental health and cellular mechanisms of disease embodies the transformative potential of early-career investigators in reshaping medical science.

The advancements spearheaded by these researchers highlight critical areas of unmet medical need and promise innovative avenues for therapeutic interventions. Through such distinguished honors, the broader medical community gains both inspiration and affirmation that the future of clinical research is in capable and visionary hands.

Subject of Research: Biological mechanisms of perinatal mood and anxiety disorders; intracellular protein mobility and its role in disease biology

Article Title: Two Weill Cornell Medicine Physician-Scientists Honored with Prestigious Early-Career Awards from ASCI for 2026

News Publication Date: 2026

Web References:

• Dr. Semra Etyemez: https://vivo.weill.cornell.edu/display/cwid-see4002
• Dr. Jesse Platt: https://vivo.weill.cornell.edu/display/cwid-jep4025

Image Credits: Credit: Weill Cornell Medicine

Keywords: Early career scientists, Psychiatry, Geriatrics, Gastroenterology

At the core of this partnership is a commitment to accelerate the translation of scientific discoveries into actionable interventions. Cardiovascular medicine is characterized by rapid advancements and complex treatment algorithms, often demanding clinicians to stay abreast of an ever-expanding corpus of literature and guidelines. By leveraging generative AI, OpenEvidence can synthesize and contextualize the latest research and recommendations from the ACC’s authoritative resources, delivering succinct, relevant information that is immediately applicable to patient care decisions. This AI-powered interface not only supports evidence-based practice but also reinforces shared decision-making between clinicians and patients through transparent and accessible medical knowledge.

The ACC’s Chief Executive Officer, Cathleen C. Gates, emphasized the transformative potential of this collaboration. She articulated a vision wherein AI integration respects and enhances the trusted judgment of clinicians rather than replacing it. The alliance aims to ensure that cardiovascular care is informed by the most current evidence while upholding stringent principles of safety and transparency. According to Gates, the union of AI technology with longstanding clinical expertise will enable providers to deliver care with heightened confidence and compassion, aligning with the ACC’s mission to improve heart health for all populations. This careful balance addresses common concerns about AI deployment in healthcare, highlighting the importance of responsible innovation.

OpenEvidence’s platform is uniquely positioned to meet the demands of diverse medical specialties by tailoring cardiovascular evidence to the varied contexts in which heart-related issues arise. Daniel Nadler, PhD, CEO of OpenEvidence, pointed out that the heart is a central concern across numerous domains—from primary care to critical emergency interventions. The AI-powered tool draws on a rich database of peer-reviewed literature, clinical guidelines, and expert consensus statements curated by the ACC to deliver precise, high-impact information. This dynamic resource empowers physicians ranging from family medicine practitioners to trauma surgeons to integrate cardiovascular science seamlessly into a broad spectrum of clinical scenarios.

To further this goal, the ACC and OpenEvidence are establishing an expert work group comprised of cardiovascular specialists who will focus on identifying knowledge gaps and addressing frequently encountered clinical questions. This consortium will play a pivotal role in developing supplemental educational materials aimed at optimizing the use of generative AI in cardiovascular practice. By scrutinizing real-world queries posed by clinicians at the point of care, the group will prioritize topics and create content that supports evidence-based treatment strategies, bridging the divide between research innovation and frontline medical practice.

The collaboration extends beyond clinical decision support to encompass educational outreach and resource development. Plans include launching an ACC/OpenEvidence AI Resource Center along with a podcast series dedicated to exploring how AI technologies are transforming cardiovascular medicine. These platforms will serve as conduits for disseminating insights on the integration of AI in healthcare, addressing both technological advancements and the ethical considerations inherent in this evolving field. Through these initiatives, the partnership aims to foster a broader dialogue among healthcare professionals about AI’s role in shaping the future of cardiac care.

A notable feature of this alliance is its integration into the ACC Annual Scientific Session via the ACC Future Hub. This initiative will grant attendees exclusive access to state-of-the-art AI-driven tools and innovations, providing a hands-on experience with technologies that have the potential to redefine clinical workflows and enhance patient management. The inclusion of AI demonstrations at one of the world’s premier cardiovascular conferences underscores the commitment of both organizations to ensure that emerging technologies are rigorously vetted, clinically relevant, and ready for adoption by cardiovascular practitioners.

The American College of Cardiology’s role as a leader in cardiovascular health is well established through its extensive educational programs, global network of chapters and sections, and influential published works such as the Journal of the American College of Cardiology (JACC) series. The ACC’s comprehensive approach combines data registries like the National Cardiovascular Data Registry (NCDR), rigorous accreditation services, and patient-centered outreach programs including CardioSmart. By partnering with OpenEvidence, the ACC is pioneering a new frontier where AI-enhanced clinical content delivery dovetails with its mission to improve heart health on a global scale.

OpenEvidence itself represents a transformative force in clinical decision support technology. Its rapid growth and adoption by over 40% of U.S. physicians reflects the platform’s effectiveness in delivering real-time, evidence-based answers at the bedside. The platform’s use of generative AI enables sophisticated medical searches tailored to the nuanced needs of healthcare providers, ensuring that decision-making is anchored in the best available evidence. Serving clinicians across more than 10,000 hospitals and medical centers, OpenEvidence has established itself as a trusted partner in clinical care, particularly for high-stakes decisions where precision and reliability are paramount.

Together, this collaboration exemplifies the convergence of AI, medical expertise, and clinical practice, fostering an ecosystem where innovation accelerates the implementation of science-based care. Through responsible and thoughtful integration of AI technologies, cardiovascular care providers are better equipped to navigate the complexities of modern medicine, ultimately improving diagnostic accuracy, therapeutic efficacy, and patient engagement. This partnership heralds a future where technology serves as a potent adjunct to human clinical acumen, driving progress in cardiac health worldwide.

Beyond immediate clinical applications, the use of generative AI within this framework raises important considerations around data governance, bias mitigation, and the preservation of clinician autonomy. The ACC and OpenEvidence’s approach prioritizes transparency in AI recommendations, sourcing every output from verified literature and ensuring alignment with established guidelines. Such diligence is critical to maintaining trust among clinicians and patients alike, preventing the pitfalls commonly associated with opaque AI systems. This paradigm of ethical AI deployment in cardiovascular medicine could serve as a model for other specialties and healthcare domains.

The partnership also holds promise for enhancing interdisciplinary collaboration, as the heart’s centrality to systemic health implicates multiple medical specialties. The integration of ACC content into OpenEvidence facilitates cross-specialty access to cardiovascular knowledge, enabling comprehensive, coordinated care approaches. For instance, emergency medicine physicians can swiftly obtain targeted cardiac guidance during acute presentations, while intensivists may leverage the platform for nuanced hemodynamic management insights. By embedding such expertise into routine practice, the partnership fosters a more unified, evidence-driven healthcare delivery landscape.

As AI continues to evolve and reshape clinical environments, the ACC and OpenEvidence’s joint efforts highlight the importance of education, research, and innovation working hand in hand. With planned resources, educational series, and dynamic clinician engagement, the collaboration aspires not only to advance cardiovascular care but also to cultivate AI literacy and ethical awareness among healthcare professionals. This multifaceted initiative underscores the transformative potential of AI when thoughtfully integrated within trusted clinical frameworks, illuminating a visionary path toward improved patient outcomes and healthcare quality.

Subject of Research: Cardiovascular clinical guidance acceleration through generative AI integration
Article Title: AI-Powered Partnership Advances Cardiovascular Care at the Point of Care
News Publication Date: Not specified
Web References: www.ACC.org
Keywords: Artificial intelligence, Clinical medicine, Cardiovascular disorders, Heart disease, Health care, Medical specialties, Doctor patient relationship, Health care delivery, Medical ethics, Medical products